The new projects, including AI efforts in Pennsylvania and three other states, are part of the British firm's pledge to invest $30 billion in the United States over the next five years.

British pharmaceutical firm GSK has pledged to invest $30bn (£22bn) in research and manufacturing in the US over the next five years. Announced at the start of US President Donald Trump's visit to the UK, the money will fund the development of next-generation factories, artificial intelligence (AI) and research labs in the US, said GSK.

GSK will invest $30 billion in U.S. R&D and manufacturing, including a new biologics factory, AI upgrades, and expanded drug and device capabilities.

GSK has announced a $30bn investment in the US over the next five years in research and development (R&D) and supply chain.

The British drugmaker’s commitment comes just as some of its pharma peers question their presence in the U.K. amid a widening row there over pricing polices.

GSK said the spending will help build new biologics facilities and upgrade existing plants in Pennsylvania, North Carolina, Maryland and Montana. CEO Emma Walmsley said the commitment reflects the company's dual footprint in both the U.

A little less than a year after targeting Moderna in an mRNA vaccine patent lawsuit, GSK is widening the scope of its litigation by throwing its rival’s next-generation COVID-19 shot into the fold. | In an amended complaint filed Thursday in Delaware federal court,

GSK has announced a $30 billion investment in the U.S. over five years to enhance R&D and manufacturing, focusing on respiratory and cancer medicines. The plan includes AI and digital tech improvements,

A new pill that combats antibiotic-resistant strains of gonorrhoea is closer to US approval, after the FDA accepted GSK’s gepotidacin for priority review.

GSK announced today that Arexvy (respiratory syncytial virus vaccine – recombinant, AS01E adjuvanted) will be offered through select provincially funded